Subtype
Large Intestinal Neoplasm
CI-CAN-00001062Explore in graph →
Non-malignant1,847 active trials21 approved drugs383 evidence items
- NCIt
- C215201
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001062Explore in graph →
Clinical trials
8,849 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06734156 | CARE-CRC: Microbiome Insights and Correlations for Risk and Outcomes in Colorectal Cancer(CARE-CRC) | recruiting | — | 400 | Gulbenkian Institute for Molecular MedicineOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07192055 | Self-sampling to Optimize Anal Lesion Outcomes(SOLO) | recruiting | N/A | 572 | Medical College of WisconsinOTHER | 1 | May 12, 2026 |
| clinicaltrials |
| NCT07579780 | Superior HypogastrIc plExus bLock During Laparoscopic Colorectal Cancer Surgery(SHIELDS) | recruiting | N/A | 170 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT07581912 | Neoadjuvant Treatment of Fulzerasib Plus Cetuximab N01 in KRAS G12C Mutated Locally Advanced Colorectal Cancer With or Without Resectable Metastases(FALCO) | recruiting | Phase 2 | 40 | Zhejiang UniversityOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT00843375 | Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas | recruiting | — | 1,200 | University of Michigan Rogel Cancer CenterOTHER | 3 | May 11, 2026 | clinicaltrials |
| NCT04920032 | Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas | recruiting | Phase 1 | 22 | University of California, IrvineOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05645510 | LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study(LONGEVITI) | recruiting | — | 75 | University of AlbertaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06758830 | Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer. | recruiting | Phase 2 / Phase 3 | 400 | National Cancer Center Affiliate of Vilnius University Hospital Santaros KlinikosOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06380816 | A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer | recruiting | Phase 1 / Phase 2 | 167 | Cancer Research UKOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07417488 | GUCY2C Prime-Boost Vaccination for Advanced Colorectal and Small Bowel Adenocarcinomas | recruiting | Phase 1 | 18 | Thomas Jefferson UniversityOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07436312 | Impact of Consumption of Ultra-processed Foods in Individuals at High Risk of Cancer(U-TRANS) | recruiting | N/A | 170 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | May 8, 2026 | clinicaltrials |
| NCT07448142 | Low-Dose Radiotherapy to Sensitize Pucotenlimab Plus CAPEOX for pMMR Locally Advanced Rectal Cancer | recruiting | Phase 2 | 50 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT03874559 | Exosomes in Rectal Cancer | recruiting | — | 30 | University of Kansas Medical CenterOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06205836 | Cemiplimab With or Without Fianlimab to Treat Older Patients With Localized or Locally Advanced MSI-H Colorectal Cancer | recruiting | Phase 2 | 44 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06239194 | Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 285 | ModeX Therapeutics, An OPKO Health CompanyINDUSTRY | 1 | May 6, 2026 | clinicaltrials |
| NCT06815406 | Recurrence Rate After Endoscopic Resection of , Laterally Spreading Tumor Granular Type (LST-G) of the Colon and Rectum: Endoscopic Mucosal Resection vs. Endoscopic Submucosal Dissection(ESD vs EMR) | recruiting | N/A | 282 | Azienda USL Reggio Emilia - IRCCSOTHER_GOV | 1 | May 6, 2026 | clinicaltrials |
| NCT06936774 | Improving Functional Outcomes and Quality of Life in Patients With Rectal Cancer After Surgery With Intensified Follow-up & Surveillance(iRECOVER) | recruiting | Phase 3 | 140 | University Hospital, Basel, SwitzerlandOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT05692024 | COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER(COMMENCER) | recruiting | Phase 1 / Phase 2 | 80 | Massachusetts General HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06249672 | Longterm Functional Outcomes in Patients Undergoing Organ Preserving Treatment for Rectal Cancer With or Without Local Excision After Chemoradiotherapy(PRESERVE) | recruiting | — | 200 | Insel Gruppe AG, University Hospital BernOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT06827366 | Lifestyle Intervention Among Participants of the French Colorectal Cancer Screening Program (LIFE-SCREEN)(LIFE-SCREEN) | recruiting | N/A | 800 | Centre Leon BerardOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07454720 | A Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 165 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | May 5, 2026 | clinicaltrials |
| NCT07503756 | JS212 Combination Therapies in Metastatic Colorectal Cancer | recruiting | Phase 2 | 80 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07566559 | Rectal Cancer Neoadjuvant Therapy-Real World Study(RC-NAT-RWS) | recruiting | — | 869 | Beijing Friendship HospitalOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT02732860 | Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host(REFLECT) | recruiting | — | 120 | University Health Network, TorontoOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT04511039 | Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer | recruiting | Phase 1 | 45 | Roswell Park Cancer InstituteOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06111105 | GUIDE.MRD-01-CRC: Clinical Validation and Benchmarking of Top Performing ctDNA Diagnostics - Colorectal Cancer | recruiting | — | 590 | Claus Lindbjerg AndersenOTHER | 5 | May 4, 2026 | clinicaltrials |
| NCT06614647 | RESPONSE: Colorectal Cancer Survivors' Follow-up Care - Now Digital and Need-based(RESPONSE) | recruiting | N/A | 400 | University of AarhusOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02781337 | Epidemiological and Molecular Colorectal Cancer Registry(EMR-CRC) | recruiting | — | 2,100 | Hospital Italiano de Buenos AiresOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT02838836 | Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers | recruiting | — | 620 | University of Missouri-ColumbiaOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07029152 | Screening for Anal Cancer in Men Who Have Sex With Men Using Pre-Exposure Prophylaxis(SCOPE) | recruiting | N/A | 296 | Universitair Ziekenhuis BrusselOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07283367 | A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. | recruiting | Phase 1 / Phase 2 | 502 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | May 1, 2026 | clinicaltrials |
| NCT07561060 | Low Rectal Cancer Treated With Total Neoadjuvant Therapy Plus Concurrent Tislelizumab Immunotherapy(TNTIT) | recruiting | Phase 1 / Phase 2 | 50 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562490 | A Randomized Controlled Trial of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy Decision-Making in High-Risk Stage III (T4N+ or T1-3N2) Colorectal Cancer(CLEAR-04) | recruiting | Phase 2 | 100 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562503 | Randomized Trial of Plasma ctDNA Methylation-Guided Adjuvant Therapy in T4N0 and Low-Risk Stage III Colorectal Cancer(CLEAR-03) | recruiting | Phase 2 | 340 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562659 | Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer(CLEAR-01) | recruiting | Phase 2 | 80 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT07562711 | Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer(CLEAR-02) | recruiting | Phase 2 | 340 | Fudan UniversityOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT01762813 | Assessment of Clinically Related Outcomes and Biomarker Analysis for Translational Integration in Colorectal Cancer(ACROBATICC) | recruiting | — | 1,200 | Helse Stavanger HFOTHER_GOV | 1 | Apr 30, 2026 | clinicaltrials |
| NCT05726136 | Fluid Challenge and Plasma Volume, During Surgery(FC-VE) | recruiting | Phase 4 | 60 | Joachim ZdolsekOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07171554 | Evaluation of a Diagnostic Test to Identify the Best Drugs for Treatment of Metastatic Colorectal Cancer(DSEE-CRC) | recruiting | N/A | 75 | Oncosyne ASINDUSTRY | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07528209 | Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 3 | 556 | Sun Yat-sen UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07558083 | FOLICOLOR TRIAL: Following Therapy Response Through Liquid Biopsy in Metatstatic Colorectal Cancer Patients(FOLICOLOR) | recruiting | Phase 3 | 150 | University Hospital, AntwerpOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07559760 | New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer | recruiting | Phase 2 | 30 | The First Hospital of Jilin UniversityOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07559825 | Early-Onset Colorectal Cancer Patients Too Young for Screening | recruiting | — | 100 | Methodist Health SystemOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT07555678 | Chemoradiotherapy and Anti-PD-1 Antibody in Anal Squamous Cell Cancer：Chase(Chase) | recruiting | Phase 2 | 241 | Fudan UniversityOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT06356584 | Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases | recruiting | Phase 2 | 62 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06589830 | TL938 and Trastuzumab for Patients With HER2-positive Metastatic Colorectal Cancer | recruiting | Phase 2 | 80 | Suzhou Teligene Ltd.INDUSTRY | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06778382 | Delayed Systemic Therapy Following Destructive Local Treatment of Pulmonary Oligometastases After No Evidence of Disease (NED) in Colorectal Cancer. | recruiting | Phase 2 | 22 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06850090 | Neoadjuvant Radiotherapy for Rectal Adenocarcinoma With Capecitabine Versus TAS-102 (Neo-REACT): A Multi-center, Randomized, Phase III Trial | recruiting | Phase 3 | 210 | Shandong Cancer Hospital and InstituteOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06911684 | Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC. | recruiting | Phase 2 | 88 | Sun Yat-sen UniversityOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07189312 | Multi-scale Spatio-Temporal Analysis of Research Data(MuSTARD) | recruiting | — | 15 | Universidad de GranadaOTHER | 1 | Apr 28, 2026 | clinicaltrials |
Data updated 23 days agoSource updated May 12, 2026source: clinicaltrials